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Summary Both urine and plasma from mice and humans with cancer cachexia have been shown to contain
higher levels of lipid mobilising activity than normal controls, even after acute starvation. There was no
significant increase in the urinary lipid mobilising activity of either mice or humans after acute starvation,
suggesting that the material in the cachectic situation was probably not due to an elevation of hormones
normally associated with the catabolic state in starvation. Further characterisation of the lipid mobilising
activity in the urine of cachectic mice using Sephadex G50 exclusion chromatography showed four distinct
peaks of activity of apparent molecular weights of >20, 3, 1.5 and <0.7 kDa. No comparable peaks of
activity were found in the urine of a non tumour-bearing mouse. The high molecular weight activity was
probably formed by aggregation of low molecular weight material, since treatment with 0.5 M NaCl caused
dissociation to material with a broad spectrum of molecular weights between 3 and 0.7 kDa. Lipolytic species
of similar molecular weights were also found in the urine of cachectic cancer patients, but not in normal urine
even after 24 h starvation. The lipid mobilising species may be responsible for catabolism of host adipose
tissue in the cachectic state.
Progressive malignant disease is often associated with the
syndrome of cachexia, characterised by loss of both adipose
tissue and muscle to such an extent that death appears to
occur by starvation (Inagaki et al., 1974). However,
numerous studies on the abnormalities in host metabolism
indicate that cancer cachexia is not the same as simple starv-
ation (Brennan, 1977) and clinically the predominant feature
distinguishing cancer cachexia from malnutrition in a non-
neoplastic condition is the absence of response to aggressive
nutritional support (Chlebowski, 1985; Wesdorp et al., 1983).
While anorexia is invariably present in most cancer patients
this may not be manifested until weight loss is established
(De Wys et al., 1981) and the metabolic effects of the tumour
may be more important in the initiation and maintenance of
the cachectic condition.
Several mediators have been proposed to be responsible
for the cachectic condition, but unfortunately most studies
do not distinguish between the cachexia which occurs in
cancer, with that in chronic infectious conditions. Thus
cachectin/tumour necrosis factor (TNF) was originally
isolated as the mediator of the biochemical changes in the
cachexia in rabbits infected with Trypanosoma brucei
(Kawakami & Cerami, 1981), although the range of cachexia
was soon extended to include cancer cachexia (Beutler &
Cerami, 1986). While TNF is capable of inducing weight loss
in animals, either by direct injection (Mahony et al., 1988) or
by implantation of tumour cells transfected with the
cachectin/TNF gene (Oliff et al., 1987), the data to support a
role for TNF in all human cachexias is less convincing. Thus,
while elevated levels of circulating TNF have been detected
in patients withm the acquired immunodeficiency syndrome
(AIDS) (Lahdevirta et al., 1988), kala-azar (visceral leish-
maniasis) and malaria (Scuderi et al., 1986), which may have
relevance to the pathogenesis of the diseases, levels of
endogenous TNF have been undetectable in cancer patients,
even in those with clinical cancer cachexia (Selby et al., 1987;
Socher et al., 1988). These results suggest that there may be
other mediators of the cachexia in cancer patients.
We have utilised a murine colon adenocarcinoma
(MAC16) to study the metabolic effects of the tumour on the
host. At a body burden of only 2% this tumour produces a
33% reduction in host body weight, without a reduction in
food or water intake (Bibby et al., 1987). Cachexia in
animals transplanted with the MAC16 tumours is associated
with the presence of circulatory catabolic factors capable of
breaking down both muscle and adipose tissue in vitro (Beck
& Tisdale, 1987). Similar elevations in lipid mobilising
activity have recently been found in the serum and urine of
patients with clinical cancer cachexia (Groundwater et al.,
1990) and this study attempts to further characterise this
activity.
Materials and methods
Pure strain NMRI mice were bred in our own colony. They
were fed a rat and mouse breeding diet (Pilsbury, Birming-
ham, UK) and water ad libitum. Male mice (weight 26 to
28 g) were transplanted in the flank with fragments of the
solid MAC16 tumour as previously described (Kitada et al.,
1981). Tumours were removed from animals with established
weight loss and homogenised (10% w/v) at 4'C in Krebs-
Ringer bicarbonate buffer, pH 7.6, and centrifuged for
10 min at 3,000 g to remove debris. Human colon carcinomas
were obtained from the operating theatre of Dudley Road
Hospital, Birmingham, UK (courtesy of Mr J. Neoptolemos)
and were homogenised under the same conditions. The
tumour supernatants were used for further characterisation.
Effect ofstarvation on lipolytic activity
Male NMRI mice (10 to 12 weeks old) were starved for 24 h
in metabolic cages. Water was provided ad libitum. Urine was
collected for further analysis and body composition analysis
was determined by the method of Lundholm et al. (1980) as
previously described (Beck & Tisdale, 1987). Blood was
removed from animals, using a heparinised syringe, by card-
iac puncture, under anaesthesia with a mixture of halothane,
oxygen and nitrous oxide. Glucose levels were determined on
whole blood with the use of the o-toluidine reagent kit
(Sigma Diagnostics, Poole, Dorset, UK). Plasma was
prepared by centrifuging whole blood for 30 s and free fatty
acid (FFA) levels were determined using a Walko NEFA C
kit (Alpha Laboratories Ltd, Hampshire, UK). Urine
creatinine concnetration was determined colourimetrically at
500 nm using a reagent kit (Sigma Diagnostics, Poole,
Dorset, UK).
Six human control subjects volunteered to starve for 24 h,
during which time only water intake was allowed. Urine and
blood samples were provided, both prior to and after starv-
ation, and were assayed for the presence of lipolytic activity.
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Exclusion chromatography
Both mouse and human urine were fractionated using a
Sephadex G50 column (1.6 x 30 cm) equilibrated with 10 mM
phosphate, pH 8.0, and eluted at a flow rate of 15 ml h'.
The void volume of the column (17 ml) was determined by
blue dextran. The effluent from the column was collected in
1 ml fractions and the lipolytic activity of 0.5 ml samples was
determined as described below. The column was calibrated
with standards (cytochrome c, aprotinin, actinomycin D and
rifampicin) of known molecular weight.
Determination oflipid mobilising activity
Mice (Strain BKW) were killed by cervical dislocation and
their epididymal adipose tissue was removed and placed in
isotonic saline, minced and incubated at 37°C for 2 h in
Krebs Ringer bicarbonate buffer, pH 7.2, containing
2 mg ml- ' of collagenase (Sigma Chemical Co., Dorset, UK)
with prior gassing with 95% 02: 5% CO2. Digestion of the
tissue was detected by the disappearance of intact pieces and
an increased turbidity of the medium. Undigested material
and non-adipose matter was removed by allowing the fat
cells to float to the surface of the buffer and the infranatant
was aspirated and replaced with fresh buffer. The washing
procedure was repeated three times to remove all collagenase,
non adipose cells and any endogenous hormones. After the
final wash the cells were suspended in an appropriate amount
of Krebs Ringer solution to give a density of 1.5 x 105
adipocytes ml-'; the cell number being enumerated with a
Neubauer haemocytometer.
Cell samples (1 ml) were removed, with continuous mixing
to maintain a homogenous cell suspension, added to the
appropriate test substance, gassed with 95% 02: 5% CO2 and
incubated for 2 h at 37°C in a shaking water bath. Control
samples containing adipocytes alone were also analysed to
measure any spontaneous glycerol release. When assaying
serum samples, a control (no adipocytes) was also included
to measure the initial amount of glycerol present in the
serum. Routinely samples of serum and urine (100 lI) were
assayed in duplicate and the assay was repeated four to five
times on each sample at different times. At the end of the
incubatiion period, 0.5 ml of the incubation buffer was added
to 0.5 ml of 10% (w/v) perchloric acid and the mixture was
shaken to ensure deproteinisation. The precipitated protein
was sedimented by centrifugation at 2,000 r.p.m. for 10 min,
the supernatant removed and neutralised with 20% (w/v)
KOH, after which the potassium perchlorate was sedimented
by centrifugation (2,000r.m.p., 10min) and the volume of
the supernatant was recorded and used to calculate the dilu-
tion factor. Assays on the supernatant were performed either
immediately, or after storge at - 20C for between 18 and
72 h. The concentration of glycerol was determined
enzymatically on 200 sl aliquots of the supernatant by the
method of Wieland (1974). The results are expressed as
jimoles glycerol released ml-' of serum or per mg creatinine
in urine per 105 adipocytes minus both the fat cell control
value and the serum or urine control value.
Statistical analysis
All results are expressed as mean ± s.e.m. from at least three
separate determinations. Differences were determined statis-
tically using Student's t-test.
Results
Despite the fact that animals bearing the MAC16 tumour
have a food and water intake not significantly different from
non tumour-bearing controls, weight loss is observed, which
increases as the tumour burden increases (Table I). We have
attempted to compare the situation with starvation for 24 h
where a similar weight loss is attained (Table I). The plasma
levels of both glucose and FFA were reduced to a similar
extent in both situations and body composition analysis
showed a similar reduction in carcass fat, although the reduc-
tion in muscle dry weight, as measured by the thigh plus
gastrocnemius muscles, was slightly less in the starved than in
the cachetic animals.
The lipolytic activity of body fluids has been measured by
the ability to liberate glycerol from freshly prepared murine
epididymal adipocytes. Previous studies (Beck & Tisdale,
1987) have employed measurement of FFA release and sub-
stantially similar results are obtained with the two methods.
The results in Table II show that both urine and plasma of
Table I Comparison of weight loss induced by starvation and by the MAC16 tumour on body composition
and plasma glucose and FFA levels in male NMRI micea
Food intake Weight loss Blood glucose Plasma FFA Body fat Muscle dry
Group (Kcal day-') (g) (mg 100 ml') (mg 100ml-') (g) weight (mg)c
Control 14.9 + 0.9 - 136 + 5 29 ± 2 1.70 + 0.09 90 ± 3
Starvationb 6.2 ± 0.2e 106 + lod 10 ± le 0.54 ± 0.15e 77 3d
Cachecticb 15.1 0.6 5.4±0.6e 108 IId 10± le 0.58±0.11e 70+2d
aThe number of animals used in each group was six to eight. Initial weight 26 to 28 g. bThe values refer to
MAC16 animals 21 days after tumour transplantation while starvation was for 24 h. cThigh plus gastrocnemius
muscle dry weights. dp<0.05 from control group. ep<0.005 from control group.
Table II Activity of lipid mobilising factors in plasma and urine during starvation
and cancer cachexia
Urine lipolytic activity p.moles Plasma lipolytic activity pmoles
glycerol (105 adipocytes)'1 glycerol (10' adipocytes)-'
(mg creatinine)' (ml plasma-')
A. Micea
Control 0.15 ± 0.065 0.020 ± 0.003
Starvation 0.14 ± 0.065 0.035 ± 0.005d
Cachexia 1.06 ± 0.168e 0.201 ± 0.030e,f
B. Human
Control 0.056 ± 0.004 0.07 ± 0.02
Starvationb 0.048 ± 0.008 0.15 0.03d
Cachexiac 0.218 + 0.023e 0.37 0.03e,f
aThe number of animals studied in each group was six to eight. bStarvation was
for a 24 h period (n = 4). cThis patient was a 53 year old female and an ovarian
carcinoma and a weight loss of 31 kg (n = 4). dp <0.05 from control group.
eP<0.001 from control group. fP<0.001 from the starvation group.848 S.A. BECK & M.-J. TISDALE
cachectic animals bearing the MAC16 tumour display an
enhanced lipolytic activity when compared with the values
for non tumour-bearing controls. Although the total plasma
lipolytic activity of animals after 24 h starvation was
significantly higher than non-starved controls, the value was
only one sixth of that found in animals bearing the MAC16
tumour. The lipolytic activity in the urine of starved animals
was not significantly different from non-starved controls.
This suggests that catabolism of body tissues in the cachectic
state is associated with an enhanced lipolytic activity, which
is not due to an elevation of hormones, normally associated
with the catabolic state in starvation.
A similar situation was observed in a patient with clinical
cancer cachexia, who also displayed an elevated plasma and
urinary lipolytic activity compared with the normal controls
(Table II). Again starvation significantly increased the plasma
lipolytic activity of normal subjects, although the value was
still significantly less than in the cachectic patient, but had
not effect on the urinary lipolytic activity.
In order to investigate the molecular species responsible for
the enhanced lipolytic activity of cachectic mouse urine an
aliquot of urine from a mouse bearing the MAC16 tumour
was subjected to exclusion chromatography using Sephadex
G50. The lipolytic activity was mainly eluted at the void
volume of the column, but was accompanied by three smaller
peaks of activity with apparent molecular weights of 3, 1.5
and <0.7 kDa (Figure la). No comparable peaks of lipolytic
activity were observed in the urine from a non tumour-
bearing mouse (Figure lc). The material eluting at the void
volume of the column appeared to be an aggregate of the low
molecular weight material, since treatment with 0.5 M NaCl
and rechromatography on Sephadex G50 gave a broad range
of activity peaks eluting between apparent molecular weights
of 3 and 0.7 kDa, with no material eluting at the void
volume (Figure lb).
Similar lipolytic species with apparent molecular weights
similar to that found in mouse urine were also observed in
the urine of a cachectic cancer patient, when subjected to
Sephadex G50 chromatography (Figure 2a). Urine from con-
trol human subjects displayed no corresponding peaks of
lipolytic activity, even after starvation for 24 h (Figure 2b).
These results suggest that the elevated lypolytic activity in the
urine of animals bearing the MAC16 tumour and in patients
with cancer cachexia is due to distinct molecular species.
Samples of fresh human colon adenocarcinomas, and in
two cases the corresponding non-involved colonic tissue,
were homogenised and assayed for lipid mobilising acitivity,
without initially having the patient characteristics. Out offive
samples assayed, only one (patient 2, Table III) was subse-
quently found to have lost weight, and the lipid mobilising
activity of this tumour was twice that of the corresponding
tumours from patients without weight loss. For those
patients where the non-involved colonic tissue was also
available, the lipolytic activity of the tumour extracts was
significantly higher than normal tissue, even though no
weight loss was observed.
Discussion
Growth of the MAC16 tumour is associated with a progres-
sive decrease in carcass lipids, although the animals consume
normal amounts of food (Beck & Tisdale, 1987). Studies in
rats have shown that the decrease in body fat cannot be
accounted for by a decreased caloric intake, since pair-fed
animals did not lose as much fat as tumour-bearing animals
(Lundholm et al., 1981). This suggests the involvement of a
lipid mobilising factor in the catabolism of host adipose
tissue in the cachectic state.
We have attempted to distinguish lipolysis in the cancer
cachectic state from that occurring during starvation. Both
states are associated with an increased plasma lipolytic
activity, although the magnitude of the increase is higher in
the cachectic state. Although a fat mobilising substance has
been detected in the urine of man and some other mammals
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Figure 1 a, Sephadex G50 chromatography of a sample (I ml)
of urine from a mouse bearing the MAC16 adenocarcinoma with
established weight loss. b, The fractions eluting at the void
volume in A were concentrated, treated with 0.5 M NaCl and
re-applied to the Sephadex column in A. c, Sephadex G50
chromatography of a sample (I ml) of urine from a non-tumour
bearing animal. Lipolytic activity is expressed as described in
Methods. Ve = elution volume. Vo = volid volume.
during conditions of active fat catabolism (Kekwick &
Pawan, 1963) we have been unable to detect an increased
lipolytic activity in the urine of normal subjects (mice or
humans) after acute starvation. Thus the enhanced lipolytic
activity appears to be specific to the cancer cachectic state.
The ability of tumours to directly stimulate lipid mobilisa-
tion was first suggested by experiments with nonviable
preparations of Krebs-2 carcinoma cells, which were able to
induce fat loss in Swiss mice to a similar extent as the viable
tumour cells (Costa & Holland, 1962). Later studies reported
a lipid mobilising factor present in both the serum of mice
bearing a thymic lymphoma and a patient with advanced
cancer (Kitada et al., 1981). The molecular weight of the
material initially reported was 5 kDa, similar to that de-
scribed in the present report, although later studies (Kitada
et al., 1982) suggested that activation only occurred on stand-
ing to give a high molecular weight material. Another lipid
mobilising factor, Toxohormone L, has been isolated from
the cell-free fluid of ascites sarcoma 180 and has been shownLIPID MOBILISATION IN CANCER CACHEXIA 849
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Figure 2 a, Sephadex G50 chromatography of a concentrated
sample (100 ml) ofurine from a male patient with teratoma and a
total weight loss of 6.3 kg at the time urine was collected. b,
Sephadex G50 chromatography of a sample (128 ml) of urine
combined from control subjects after 24 h of starvation. Lipolytic
activity is expressed as described in Methods.
to produce anorexia when injected into mice (Masuno et al.,
1981).
We have now shown that urine of both mice and humans
with cancer cachexia appears to contain distinct molecular
species with lipid mobilising activity which are absent during
starvation. The true lipid mobilising fractions are probably of
low molecular weight since the high molecular weight
material is capable of being dissociated to the lower
molecular weight forms with salt, suggesting an aggregation
or non specific attachment to urinary proteins. We have
recently shown (Groundwater et al., 1990) that patients with
cancer cachexia have increased levels of both serum and
urinary lipid mobilising activity which increases with increas-
ing weight loss up to a maximum body weight loss of
16-20%. Higher levels of lipolytic activity are also present in
Table III Lipid mobilising activity of human colon
adenocarcinomas and non-involved colonic tissue
Patient Sex Age Weight loss Lipolytic activitya
I Female 61 0 0.021 ±0.004
2 Male 50 12.7 0.047 ± 0.006c
3 Male 62 0 0.025 + 0.007
4 Female 68 0 0.023 + 0.006
(0.010 0.002)b
5 Male 68 0 0.021 ± 0.007
(0.002 0.004)b
aResults are expressed as tmoles glycerol released per ml tissue
homogenate per 105 adipocytes per h. bValues for non-involved
colonic tissue. CP<0.001 from patients 1, 3, 4 and 5 by Student's
t-test.
a tumour extract from a patient with an adenocarcinoma of
the colon with established weight loss, than from tumours
from patients without weight loss, although preliminary data
suggests that the lipolytic activity of the other tumours is
higher than the normal colonic mucosa. Similar results were
obtained in the MAC series of murine colon adenocar-
cinomas (Beck & Tisdale, 1987) where, although the
cachexia-inducing MAC16 tumour had the highest lipolytic
activity, significant activity was also found in the other
tumour types. This suggests that tumours may have a system
for obtaining lipids from the host, which may be utilised
when de novo biosynthesis is insufficient to meet the
metabolic demands.
Tumours obtain a substantial amount of preformed fatty
acid from the host (Spector, 1975) either as circulating FFA
(Mermier & Baker, 1974) or to a lesser extent from the
triacylglycerols contained in plasma lipoproteins (Brenneman
& Spector, 1974), despite the fact that tumours can synthesise
fatty acids from glucose (Kannan et al., 1980). Conditions
which stimulate mobilisation of fatty acids from adipose
tissue such as diabetes mellitus (Sauer & Dauchy, 1987a) and
acute fasting (Sauer & Dauchy, 1987b) also stimulate the
growth of the tumour. These findings suggest that the
availability of nutrients derived from host fat stores may be
rate limiting for tumour growth in vivo, which could provide
some logic for the production by tumour cells of a substance
capable, through some sort of receptor interaction, of
mobilising lipids from host fat stores.
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